Farr v. Phase-I Molecular Toxicology, Inc. (In Re Phase-I Molecular Toxicology, Inc.)

287 B.R. 571, 49 Collier Bankr. Cas. 2d 1375, 2002 Bankr. LEXIS 1499, 2002 WL 31906286
CourtUnited States Bankruptcy Court, D. New Mexico
DecidedDecember 19, 2002
Docket19-10327
StatusPublished
Cited by9 cases

This text of 287 B.R. 571 (Farr v. Phase-I Molecular Toxicology, Inc. (In Re Phase-I Molecular Toxicology, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. New Mexico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Farr v. Phase-I Molecular Toxicology, Inc. (In Re Phase-I Molecular Toxicology, Inc.), 287 B.R. 571, 49 Collier Bankr. Cas. 2d 1375, 2002 Bankr. LEXIS 1499, 2002 WL 31906286 (N.M. 2002).

Opinion

*574 MEMORANDUM OPINION

MARK B. MCFEELEY, Chief Judge.

THIS MATTER came before the Court on the Motion for Summary Judgment (“Motion”) filed by Defendants TD Javelin Capital Fund II, L.P. (“TD”) and TullisDickerson Capital Focus II, L.P. (“Tullís”), or jointly, (“Tullis-Dickerson”), by and through their attorneys of record, Modrall, Sperling, Roehl, Harris & Sisk, P.A. (Paul M. Fish). Plaintiffs’ Complaint for Declaratory Judgment and Equitable Subordination Under § 510(c) (“Complaint”) filed by Spencer Farr Ph.D and Susanne Roubidoux, for themselves and all creditors of the estate, by and through their attorneys of record, Rodey, Dickason, Sloan, Akin & Robb, P.A. (James A. Askew), seeks a determination that certain secured loans granted by Tullis-Dickerson to the Debtor should be re-characterized as capital contributions. Alternatively, Plaintiffs seek to equitably subordinate Tullis-Dickerson’s claim pursuant to 11 U.S.C. § 510(c).

At the final hearing on confirmation of the Debtor’s plan of reorganization, held October 31, Plaintiffs and Tullis-Dickerson offered evidence and argument on the issue of equitable subordination of TullisDickerson’s claim, which the Court will take into consideration in ruling on TullisDickerson’s Motion for Summary Judgment. 1 After considering the pleadings, the Motion and supporting memorandum, the response 2 thereto, and the evidence and argument previously offered at the final hearing on confirmation, and being otherwise fully informed, the Court finds that summary judgment is proper as a matter of law. Plaintiffs’ Response also seeks a continuance pursuant to Rule 7056(f) to allow additional time for Plaintiffs to respond to the Motion. The Court denies this request.

DISCUSSION

Summary judgment is proper when there are no genuine issues of material fact and the moving party is entitled to judgment as a matter of law. Rule 56(c), Fed.R.Civ.P., as incorporated into the Federal Rules of Bankruptcy Procedure by Rule 7056, Fed. R. BankrP. The movant bears the initial burden of showing an absence of a genuine issue of material fact; however, “the movant need not negate the non-movant’s claim, but need only point to an absence of evidence to support the nonmovant’s claim.” In re Harris, 209 B.R. 990, 995 (10th Cir. BAP 1997) (citations omitted); see Celotex Corp. v. Catrett, 477 U.S. 317, 323, 106 S.Ct. 2548, 2552, 91 L.Ed.2d 265 (1986) (finding no requirement in Rule 56 that movant support its motion with materials negating opponent’s claim). Once this initial burden is met, the non-movant may not rely solely upon the allegations contained in the pleadings, but must offer evidence beyond the scope of the pleadings to show the presence of genuine issues of material fact sufficient for trial. Celotex Corp. v. Catrett, 477 U.S. 317, 324-25, 106 S.Ct. 2548, 2553-54, 91 L.Ed.2d 265 (1986). In determining whether summary judgment should be granted, the Court will view the record in the light most favorable to the party opposing summary judgment. In re Harris, 209 B.R. 990, 995 (10th Cir. BAP 1997).

*575 The following facts are not in dispute:

1. TD and Tullís are shareholders of the Debtor and claim to be creditors in the Debtor’s bankruptcy. See Complaint, ¶ 7.; Answer, ¶ 1.

2. On or about June 18, 2002, Debtor executed and delivered to TD a promissory note in the principal amount of $150,000.00 plus interest at the rate of 10% per annum, payable on demand. See Complaint, ¶ 12; Answer, ¶ 1.

3. On or about June 18, 2002, Debtor executed and delivered to Tullís a promissory note in the principal amount of $150,000.00 plus interest at the rate of 10% per annum, payable on demand. See Complaint, ¶ 14; Answer, ¶ 1.

4. TD and Tullís each advanced $150,000.00 to the Debtor. See Complaint, ¶¶ 11. and 13; Answer ¶ 3.

5. On or about June 18, 2002, as security for the promissory notes, Tullis-Dickerson obtained a security interest in all or substantially all of the Debtor’s assets, described generally as accounts, intellectual property and related property rights, commercial tort claims, stock in subsidiary, deposit accounts, contract rights, equipment, goods, inventory, general intangibles, fixtures, and other assets, as described more fully in a Security Agreement, Patent and Trademark Security Agreement, and Stock Pledge Agreement entered into by the Debtor, TD, and Tullís. See Complaint, ¶ 15; Answer, ¶ 1.

6. Tullis-Dickerson filed a financing statement with the Secretary of State of Delaware to perfect the security interest claimed by TD and Tullís in the Debtor’s property. See Complaint, ¶ 16; Answer, ¶1.

7. At the time Tullis-Dickerson made the advances and the Debtor executed the promissory notes, the Debtor could not have borrowed a similar amount of money from an informed outside source. See Complaint, ¶ 18; Answer, ¶ 1. Tullis-Dickerson was aware that the Debtor was unable to obtain funding from another source at the time Tullis-Dickerson made the advances. See Complaint, ¶ 31; Answer, ¶ 1.

8. Prior to the granting of the loans at issue in this adversary proceeding, TullisDickerson, and other Tullis-Dickerson entities had already invested over ten million dollars as stockholders of the Debtor. See Exhibit 6, Phase I Molecular Toxicology Capitalization as of 4/19/02, attached to the Memorandum Brief in Support of Motion for Summary Judgment (“Memorandum Brief’), and attached as Exhibit C to Debt- or’s Second Disclosure Statement.

9. The Debtor’s then Chairman of the Board, Mr. Robert Ivy, and the Debtor’s Chief Executive Officer, Vince Kazmier, who are not investors or employees of Tullis-Dickerson, initially approached Tullis-Dickerson with a request for the $300,000.00 loan. (Uncontroverted testimony of Richard J. Miller, an independent consultant for Tullis-Dickerson, admitted into evidence at the final hearing on confirmation of the Debtor’s proposed plan); See Exhibit C, attached to the Motion.

10. When the loan request was made, the Debtor anticipated selling assets of its Belgian subsidiary and other assets which would generate significant cash sometime in early fall. (Uncontroverted testimony of Richard J. Miller admitted into evidence at the final hearing on confirmation of the Debtor’s proposed plan); See Exhibit C, attached to Motion.

11. Tullis-Dickerson was initially reluctant to grant the loans. (Uncontroverted testimony of Richard J. Miller admitted into evidence at the final hearing on confirmation of the Debtor’s proposed plan);

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
287 B.R. 571, 49 Collier Bankr. Cas. 2d 1375, 2002 Bankr. LEXIS 1499, 2002 WL 31906286, Counsel Stack Legal Research, https://law.counselstack.com/opinion/farr-v-phase-i-molecular-toxicology-inc-in-re-phase-i-molecular-nmb-2002.